Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Randomized, Double-blind, Controlled Phase III Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35months

NCT06049927 is registered in ClinicalTrials.gov with Sinovac Biotech Co., Ltd as lead sponsor.

NCT NCT06049927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06049927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Randomized, Double-blind, Controlled Phase III Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35months
Lead sponsor
Sinovac Biotech Co., Ltd
Phase
Phase 3
Overall status
Completed
Start date
September 16, 2023
Completion date
May 23, 2024
Enrollment
3,300 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

seasonal influenza